US Stocks Open Lower; Housing Market Index Drops In September
U.S. stocks traded lower this morning, after recording losses in the previous week.
Virios Therapeutics Shares Tank After Failing Fibromyalgia Study
Virios Therapeutics Inc’s (NASDAQ:VIRI) shares crashed after its FORTRESS Phase 2b trial of IMC-1 antiviral combination therapy for fibromyalgia failed…
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
Gainers
Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…
Virios Therapeutics Commences Mid-Stage Long-COVID Study
Virios Therapeutics (Nasdaq: VIRI) has initiated patient dosing in its exploratory Long-COVID trial evaluating IMC-2 (valacyclovir + celecoxib).
Virios Therapeutics’ Announced Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM"), today announced commencement of enrollment in its exploratory Long-COVID trial.
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
